Onureg Tablet, Film Coated
Product Images NDC 59572-730

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Onureg (NDC 59572-730). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Onureg 01)

This appears to be a chemical formula consisting of three letters, H, O, and OH. It is unclear what the intended substance or compound is without further context.*

FDA Label Image

Figure 1 (Onureg 02)

This is a survival analysis table. It shows the time in months from randomization and the number of patients at risk, treated with ONUREG or Placebo. The last row displays the number of patients at risk at each month.*

FDA Label Image

Principal Display Panel (200 mg Bottle Label)

FDA Label Image

Principal Display Panel (300 mg Bottle Label)

This is a description of ONUREG (azacitidine) tablets, containing 200 mg of the active ingredient per tablet. It comes in a blister card with a total of 7 tablets, with instructions to swallow the tablets whole without cutting, crushing, or chewing them. The drug is indicated for use on specific days and caution should be taken as it is considered a hazardous agent. The NDC number is 59572-730-07 and it is only available with a prescription.*

FDA Label Image

Onureg 05

The text is a description of a drug called "ONUREG" with NDC code 59572-730-07. It contains azacitidine and comes in tablets with a strength of 200mg. The tablets are packed in a blister card and caution is required while handling the drug as it is a hazardous agent. The text also provides some operational instructions for taking the tablets.*

FDA Label Image

Onureg 06

ONUREG (azacitidine) tablets are a prescription medication containing 200 mg of azacitidine, used to treat certain types of bone marrow disorders. These tablets should be stored at temperatures between 20°C and 25°C and kept out of reach of children. Each package contains one blister card with seven tablets. The medication should be swallowed whole without cutting, crushing, or chewing. Manufactured by Celgene Corporation, a subsidiary of Bristol Myers Squibh company, ONUREG tablets are a hazardous agent and require caution during use.*

FDA Label Image

Onureg 07

This is a description of a medication called "Onureg" produced by Colgens Corporation. It is a hazardous agent contained in a bottle with 14 tablets that should be swallowed whole, not chewed or crushed. The bottle's contents should be stored in a safe and cool place. There are instructions and warnings on the label. The medication is manufactured in Switzerland, and the label also provides the address and phone number of Colgens Corporation.*

FDA Label Image

Onureg 08

This is a description for ONUREG (azacitidine) tablets. Each blister card contains 7 tablets of 300mg. The tablets are Rx only and should not be swallowed or chewed. The hazardous agent should be handled with caution. The instructions show the recommended dosage on DAYS 1 to 7. This product has an NDC code of 59572-740-07.*

FDA Label Image

Onureg 09

This is a medication package containing 7 tablets of Onureg, which is a brand name for Azacitidine. One tablet of this medicine contains 300 mg of Azacitidine. The operating instructions to take the medicine suggest pushing the tablet through the blister card and swallowing it whole. The package contains a caution that the medicine is a hazardous agent. However, there is illegible and nonsensical text included in the package making it difficult to understand.*

FDA Label Image

Onureg 10

Azacitidine tablets, with NDC 59572-740-07, are indicated for treating cancer. Each tablet contains 300 mg of azacitidine. These tablets should be stored between 20°C-25°C (68°F-77°F), and excursions limited to 16°C-30°C (59°F-86°F) are allowed. They must be kept in the original aluminum-aluminum blister cards and children should be kept away from them. The recommended dosage should be taken from information provided. The tablets should be swallowed whole and not crushed or chewed. Celgene Corporation, a fully owned subsidiary of Bristol Myers Squibb Company, manufactured this medicine in Switzerland. One blister card contains seven tablets. The text contains only one phrase, @ONUREG, which seems to be out of place because ONUREG is a separate drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.